Disc Medicine, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Disc Medicine, Inc. (IRON) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-30
- Disc Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.04M.
- Disc Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.54M, a 724.39% decline year-over-year.
- Disc Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $247.00K.
- Disc Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $445.00K, a 44.44% decline year-over-year.
- Disc Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $676.00K, a 133.91% increase from fiscal 2024.
- Disc Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $289.00K.
- Disc Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $0.00.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.04M 10-Q · filed 2026-07-30 | -$2.57M 10-Q · filed 2026-07-30 | -$2.33M derived: sum of 3 quarters · filed 2026-07-30 | -$1.88M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$1.54M 10-Q · filed 2026-05-05 | -$1.29M derived: sum of 2 quarters · filed 2026-05-05 | -$844.00K derived: sum of 3 quarters · filed 2026-05-05 | -$1.11M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $692.00K derived: sum of 2 quarters · filed 2026-02-26 | $430.00K derived: sum of 3 quarters · filed 2026-07-30 | $676.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $445.00K 10-Q · filed 2025-11-06 | $183.00K derived: sum of 2 quarters · filed 2026-07-30 | $429.00K 10-Q · filed 2025-11-06 | -$23.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$262.00K 10-Q · filed 2026-07-30 | -$16.00K 10-Q · filed 2026-07-30 | -$468.00K derived: sum of 3 quarters · filed 2026-07-30 | $333.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $246.00K 10-Q · filed 2026-05-05 | -$206.00K derived: sum of 2 quarters · filed 2026-05-05 | $595.00K derived: sum of 3 quarters · filed 2026-05-05 | $535.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $349.00K derived: sum of 2 quarters · filed 2026-02-26 | $289.00K derived: sum of 3 quarters · filed 2026-02-26 | $289.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $801.00K 10-Q · filed 2025-11-06 | $741.00K derived: sum of 2 quarters · filed 2025-11-06 | $741.00K 10-Q · filed 2025-11-06 | $741.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$60.00K 10-Q · filed 2025-08-07 | -$60.00K 10-Q · filed 2025-08-07 | -$60.00K derived: sum of 3 quarters · filed 2026-02-26 | -$60.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |